Roche has announced a significant $50 billion investment in the U.S. over the next five years, focusing on expanding its manufacturing and research infrastructure. This move comes as pharmaceutical companies prepare for potential tariffs from the Trump administration, encouraging them to increase local production of medicines. Existing sites will be expanded, and new facilities will be established, including a gene therapy plant in Pennsylvania and a major R&D center near Boston specializing in AI and metabolic research. This investment showcases Roche's commitment to domestic manufacturing and innovation in response to evolving industry challenges.
Roche's commitment marks a significant investment of $50 billion in the U.S. over five years, aiming to enhance manufacturing and research infrastructure amid proposed tariffs.
The company aims to avoid potential tariffs by increasing U.S. manufacturing of its medications, with new facilities and expansions planned across various states.
Roche's planned investments include a new gene therapy plant in Pennsylvania and an advanced R&D center focused on AI and metabolism in Massachusetts.
The companyâs expansions reflect a broader trend where pharma firms invest domestically to navigate future tariffs and adapt to emerging market demands.
Collection
[
|
...
]